What Is The Current and Historic Market Size Analysis Of The Gene Delivery Technologies Market?
The gene delivery technologies market has seen considerable growth due to a variety of factors.
•The market size for gene delivery technologies has seen a speedy escalation in recent years. Projections are that it will expand from $3.79 billion in 2024 to $4.3 billion in 2025, indicating a compound annual growth rate (CAGR) of 13.6%.
The growth witnessed in the historic period has been fueled by improved knowledge of genetic disorders, advances in cell therapy, the progression of nanotechnology, an upswing in gene therapy trials, and an augmentation in research funding.
What Are The Predictions for The Gene Delivery Technologies Market Size In The Coming Years?
The gene delivery technologies market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for gene delivery technologies is anticipated to experience swift expansion in the coming years, reaching a value of "$7.44 billion by 2029 with a 14.7% Compound Annual Growth Rate (CAGR).
This predicted rise during the forecast period is linked to the evolution of precision medicine, improvements in regulatory frameworks, the spread of gene therapy, and the growth of non-viral delivery systems. Other significant market trends for the same timeframe are its applications in treating rare diseases, the increase in clinical trials, targeted drug delivery mechanisms, cell therapy development, and the creation of gene editing instruments.
Which Drivers Are Accelerating Growth In The Gene Delivery Technologies Market?
The gene delivery technologies market is projected to grow with the rise in the number of cell and gene therapies. These therapies, which aim to treat or alleviate diseases by modifying a patient's genetic and cellular structure, are primarily propelled by advancements in gene editing technologies. Such technologies play a crucial role in creating and marketing cell and gene therapies. For example, as noted by the Association of the British Pharmaceutical Industry, a UK-focused trade organization, in August 2024, the UK medicines regulator traditionally approves around two ATMPs every year. However, this is projected to increase to 10–15 approvals annually by 2030. The number of patients receiving these treatments in the UK is expected to rise from 2,500 in 2021 to potentially 10,000 yearly by 2028. Hence, the amplification of cell and gene therapies contributes to the growth of the gene delivery technologies market.
What Are The Core Segments Of The Global Gene Delivery Technologies Market?
The gene delivery technologies market covered in this report is segmented –
1) By Mode: Biological, Chemical, Physical
2) By Method: Ex Vivo, In Vivo, In Vitro
3) By Application: Gene Therapy, Cell Therapy, Vaccines, Research
Subsegments:
1) By Biological: Viral Vectors, Bacterial Vectors, Lipid Nanoparticles
2) By Chemical: Cationic Lipids, Polymers, Chemical Transfection Agents
3) By Physical: Electroporation, Microinjection, Gene Gun, Sonoporation
Pre-Book The Gene Delivery Technologies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Gene Delivery Technologies Market Size?
The rise of technological advancements has become a prominent trend in the gene delivery technologies market. Key players in the market are focusing on developing technologically progressive products to fortify their market standing. For example, Aera Therapeutics, an American biotechnology corporation, introduced Aera's Platform delivery technology in February 2023 to unravel the power of genetic medicine. The precision of the PNP technology in targeting RNA molecules implicated in disease progression showcases its uniqueness. It also makes targeted gene editing possible within a patient's cells, suggesting the potential for individualized gene therapies.
Who Are the Key Players in the Gene Delivery Technologies Market?
Major companies operating in the gene delivery technologies market include:
• Thermo Fisher Scientific Inc.
• QIAGEN NV
• Horizon Discovery Group Co
• OriGene Technologies Inc.
• Oxford Biomedica Solutions LLC
• SignaGen Laboratories LLC
• Vectalys SAS
• Takara Bio Inc.
• Bio-Rad Laboratories Inc.
• System Biosciences LLC
• Promega Corporation
• Hoffmann-La Roche AG
• Catalent Inc.
• Avantor
• Pfizer Inc.
• Becton Dickinson and Company
• Novartis AG
• Intellia Therapeutics Inc.
• Editas Medicine Inc.
• CRISPR Therapeutics AG
• Spark Therapeutics Inc.
• Bluebird Bio Inc.
• Sarepta Therapeutics Inc.
• Regenexxbio Inc.
• Beam Therapeutics Inc.
• Verve Therapeutics Inc.
• Arrowhead Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Moderna Inc.
• BioNTech SE
• Translate Bio Inc.
• CureVac N.V.
• Lonza Group AG
What are the Regional Insights into the Gene Delivery Technologies Market?
North America was the largest region in the gene delivery technologies market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global gene delivery technologies market report during the forecast period. The regions covered in the gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
